	US 12,203,077 B2
	Fusion proteins for improved precision in base editing
Jia Chen, Shanghai (CN); Xingxu Huang, Shanghai (CN); Li Yang, Shanghai (CN); Bei Yang, Shanghai (CN); Xiaosa Li, Shanghai (CN); Ying Wang, Shanghai (CN); and Yajing Liu, Shanghai (CN)
Assigned to ShanghaiTech University, Shanghai (CN)
Appl. No. 16/640,337
Filed by ShanghaiTech University, Shanghai (CN)
PCT Filed Aug. 28, 2018, PCT No. PCT/CN2018/102750 § 371(c)(1), (2) Date Feb. 19, 2020, PCT Pub. No. WO2019/042284, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. PCT/CN2017/100131 (WO), filed on Sep. 1, 2017.
Prior Publication US 2020/0354729 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C07K 14/32 (2006.01); C12N 9/78 (2006.01); C12N 15/10 (2006.01); C12N 15/79 (2006.01)

CPC C12N 15/79 (2013.01) [C07K 14/32 (2013.01); C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 15/102 (2013.01); C07K 2319/09 (2013.01); C12Y 305/04005 (2013.01)]

13 Claims

1. A fusion protein comprising a first fragment comprising a cytidine deaminase and a second fragment comprising a catalytically inactive Lachnospiraceae bacterium Cpf1 (dLbCpf1), wherein the dLbCpf1 comprises the amino acid sequence of SEQ ID NO:5, wherein the cytidine deaminase is an apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) protein selected from the group consisting of a wild-type rat APOBEC1, a wild-type human APOBEC3A, a wild-type human activation-induced (cytidine) deaminase (AID), and a variant comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 or 4.